Bazedoxifene As a Potential Cancer Therapeutic Agent Targeting IL-6/GP130 Signaling

Overview

Journal Curr Oncol

Publisher MDPI

Specialty Oncology

Date 2024 Oct 25

PMID 39451730

Authors

Changyou Shi

Taylor Bopp

Hui-Wen Lo

Katherine Tkaczuk

Jiayuh Lin

Affiliations

Soon will be listed here.

Abstract

Targeting the interleukin-6 (IL-6)/glycoprotein 130 (GP130) signaling pathway holds significant promise for cancer therapy given its essential role in the survival and progression of various cancer types. We have identified that bazedoxifene (BZA), a Food and Drug Administration (FDA)-approved drug used for the prevention of postmenopausal osteoporosis, when combined with conjugated estrogens in Duavee, also has a novel function as an inhibitor of IL-6/GP130 interaction. BZA is currently under investigation for its potential anticancer therapeutic function through the inhibition of the IL-6/GP130 pathway. Numerous studies have highlighted the efficacy of BZA (monotherapy or combined with other chemotherapy drugs) in impeding progression across multiple cancers. In this review, we mainly focus on the anticancer activity of BZA and the underlying anticancer mechanism through inhibition of the IL-6/GP130 pathway, aiming to provide valuable insights for the design and execution of further research and the potential repositioning of BZA in oncological clinical trials.

Citing Articles

Chronic Stress Mediates Inflammatory Cytokines Alterations and Its Role in Tumorigenesis.

Liu Z, Lei M, Bai Y J Inflamm Res. 2025; 18:1067-1090.

PMID: 39871957 PMC: 11769853. DOI: 10.2147/JIR.S485159.

References

Li S, Tian J, Zhang H, Zhou S, Wang X, Zhang L . Down-regulating IL-6/GP130 targets improved the anti-tumor effects of 5-fluorouracil in colon cancer. Apoptosis. 2018; 23(5-6):356-374. DOI: 10.1007/s10495-018-1460-0. View

Hao Y, Yan Z, Zhang A, Hu S, Wang N, Luo X . IL-6/STAT3 mediates the HPV18 E6/E7 stimulated upregulation of MALAT1 gene in cervical cancer HeLa cells. Virus Res. 2020; 281:197907. DOI: 10.1016/j.virusres.2020.197907. View

Wu X, Cao Y, Xiao H, Li C, Lin J . Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy. Mol Cancer Ther. 2016; 15(11):2609-2619. PMC: 5310670. DOI: 10.1158/1535-7163.MCT-15-0921. View

Xu S, Grande F, Garofalo A, Neamati N . Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer. Mol Cancer Ther. 2013; 12(6):937-49. DOI: 10.1158/1535-7163.MCT-12-1082. View

Wei L, Kuo M, Chen C, Chou C, Lai K, Lee C . Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene. 2003; 22(10):1517-27. DOI: 10.1038/sj.onc.1206226. View

Turkson J, Jove R . STAT proteins: novel molecular targets for cancer drug discovery. Oncogene. 2001; 19(56):6613-26. DOI: 10.1038/sj.onc.1204086. View

Figueroa-Magalhaes M, Jelovac D, Connolly R, Wolff A . Treatment of HER2-positive breast cancer. Breast. 2013; 23(2):128-136. PMC: 4466908. DOI: 10.1016/j.breast.2013.11.011. View

Brouckaert O, Wildiers H, Floris G, Neven P . Update on triple-negative breast cancer: prognosis and management strategies. Int J Womens Health. 2012; 4:511-20. PMC: 3469230. DOI: 10.2147/IJWH.S18541. View

Fu S, Chen X, Lo H, Lin J . Combined bazedoxifene and paclitaxel treatments inhibit cell viability, cell migration, colony formation, and tumor growth and induce apoptosis in breast cancer. Cancer Lett. 2019; 448:11-19. DOI: 10.1016/j.canlet.2019.01.026. View

10.

Higgins M, Stearns V . Understanding resistance to tamoxifen in hormone receptor-positive breast cancer. Clin Chem. 2009; 55(8):1453-5. DOI: 10.1373/clinchem.2009.125377. View

11.

Zhang R, Wang T, Lin J . Synergistic Effect of Bazedoxifene and PARP Inhibitor in the Treatment of Ovarian Cancer Regardless of BRCA Mutation. Anticancer Res. 2021; 41(5):2277-2286. DOI: 10.21873/anticanres.15003. View

12.

Liu A, Liu Y, Xu Z, Yu W, Wang H, Li C . Novel small molecule, XZH-5, inhibits constitutive and interleukin-6-induced STAT3 phosphorylation in human rhabdomyosarcoma cells. Cancer Sci. 2011; 102(7):1381-7. PMC: 11158026. DOI: 10.1111/j.1349-7006.2011.01932.x. View

13.

Morgan E, Arnold M, Gini A, Lorenzoni V, Cabasag C, Laversanne M . Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut. 2023; 72(2):338-344. DOI: 10.1136/gutjnl-2022-327736. View

14.

Biller L, Schrag D . Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. JAMA. 2021; 325(7):669-685. DOI: 10.1001/jama.2021.0106. View

15.

Tian J, Chen X, Fu S, Zhang R, Pan L, Cao Y . Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer. Breast Cancer Res Treat. 2019; 175(3):553-566. DOI: 10.1007/s10549-019-05183-2. View

16.

Leslie K, Lang C, Devgan G, Azare J, Berishaj M, Gerald W . Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3. Cancer Res. 2006; 66(5):2544-52. DOI: 10.1158/0008-5472.CAN-05-2203. View

17.

Narazaki M, Witthuhn B, Yoshida K, Silvennoinen O, Yasukawa K, Ihle J . Activation of JAK2 kinase mediated by the interleukin 6 signal transducer gp130. Proc Natl Acad Sci U S A. 1994; 91(6):2285-9. PMC: 43355. DOI: 10.1073/pnas.91.6.2285. View

18.

Lin L, Hutzen B, Zuo M, Ball S, DeAngelis S, Foust E . Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res. 2010; 70(6):2445-54. PMC: 2843552. DOI: 10.1158/0008-5472.CAN-09-2468. View

19.

Zhao P, Li H, Fu H, Liu X, Liu Y, Wu J . Bazedoxifene enhances paclitaxel efficacy to suppress glioblastoma via altering Hippo/YAP pathway. J Cancer. 2020; 11(3):657-667. PMC: 6959043. DOI: 10.7150/jca.38350. View

20.

Chen C, Loy A, Cen L, Chan C, Hsieh F, Cheng G . Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells. BMC Cancer. 2007; 7:111. PMC: 1964761. DOI: 10.1186/1471-2407-7-111. View